Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antisense oligonucleotides
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Sun Yat-sen University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2020
Details:
Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NI007
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Neurimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2020
Details:
Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
